Table 2. Univariate analysis for overall survival, progression-free survival, and local recurrence free survival.
| Covariate | n | OS HR | p | PFS HR | p | LRFS HR | p |
|---|---|---|---|---|---|---|---|
| (95% CI) | (95% CI) | (95% CI) | |||||
| Sex | |||||||
| Male | 71 | 1 | 0.39 | 1 | 0.34 | 1 | 0.85 |
| Female | 104 | 1.20 (0.79–1.82) | 0.83 (0.56–1.22) | 0.96 (0.65–1.44) | |||
| Age | |||||||
| <60 y | 100 | 1 | 0.6 | 1 | 0.61 | 1 | 0.98 |
| ≥60 y | 74 | 0.90 (0.59–1.36) | 1.11 (0.75–1.63) | 0.98 (0.67–1.49) | |||
| ECOG PS | |||||||
| 0-1 | 143 | 1 | 0.01 | 1 | 0.02 | 1 | 0.006 |
| 2 | 32 | 1.84 (1.15–2.96) | 1.64 (1.07–2.52) | 1.86 (1.19–2.92) | |||
| T | |||||||
| T1-2 | 39 | 1 | 0.62 | 1 | 0.54 | 1 | 0.56 |
| T3-4 | 116 | 1.14 (0.68–1.89) | 1.16 (0.72–1.88) | 1.16 (0.71–1.84) | |||
| N | |||||||
| N0-1 | 118 | 1 | 0.003 | 1 | 0.002 | 1 | 0.002 |
| N2-3 | 57 | 1.87 (1.24–2.83) | 1.86 (1.26–2.74) | 1.87 (1.26–2.77) | |||
| Tumor size | |||||||
| ≤5 cm | 116 | 1 | 0.02 | 1 | 0.04 | 1 | 0.03 |
| >5 cm | 59 | 1.63 (1.07–2.50) | 1.53 (1.03–2.27) | 1.59 (1.06–2.38) | |||
| RT technique | |||||||
| 3D-conformal | 30 | 1 | 0.84 | 1 | 0.88 | 1 | 0.83 |
| IMRT | 145 | 0.95 (0.58–1.56) | 1.04 (0.64–1.68) | 1.05 (0.65–1.72) | |||
| RT dose | |||||||
| ≤54 Gy | 73 | 1 | 0.3 | 1 | 0.1 | 1 | 0.25 |
| >54 Gy | 102 | 0.81 (0.53–1.22) | 0.72 (0.49–1.06) | 0.8 (0.54–1.18) | |||
| Treatment period | |||||||
| 2005–2013 | 46 | 1 | 0.93 | 1 | 0.46 | 1 | 0.88 |
| 2014–2021 | 129 | 1.02 (0.63–1.67) | 0.84 (0.52–1.35) | 0.97 (0.63–1.48) | |||
| Tx response | |||||||
| CR | 96 | 1 | <0.001 | 1 | <0.001 | 1 | <0.001 |
| Non-CR | 73 | 4.8 (3.06–7.56) | 4.54 (3.00–6.89) | 5.30 (3.43–8.20) | |||
| Conc. ChT | |||||||
| Cisplatin | 89 | 1 | 0.56 | 1 | 0.87 | 1 | 0.58 |
| Others | 86 | 0.88 (0.58–1.34) | 0.87 (0.59–1.28) | 0.90 (0.60–1.33) |
Abbreviations: ChT: chemotherapy, CI: confidence interval, Conc.: concurrent, CR: complete response, HR: hazard ratio, ECOG PS: Eastern Cooperative Oncology Group performance score, IMRT: intensity modulated radiotherapy, LRFS: local recurrence free survival, OS: overall survival, PFS: progression-free survival, RT: radiotherapy, Tx: treatment.